GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) ROC %: 83.05% (As of Mar. 2026)


NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
73 GF Score
Price ₹2,354.80
GF Value ₹2,614.23
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals ROC %?

GlaxoSmithKline Pharmaceuticals NSE:GLAXO -0.50% 73 ROC % is 83.05% as of Mar. 2026. GuruFocus rates NSE:GLAXO with a GF Score™ of 73/100 and a GF Value™ of ₹2,614.23 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. GlaxoSmithKline Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 83.05%.

As of today (2026-06-26), GlaxoSmithKline Pharmaceuticals's WACC % is 11.31%. GlaxoSmithKline Pharmaceuticals's ROC % is 74.77% (calculated using TTM income statement data). GlaxoSmithKline Pharmaceuticals generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


GlaxoSmithKline Pharmaceuticals  (NSE:GLAXO) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, GlaxoSmithKline Pharmaceuticals's WACC % is 11.31%. GlaxoSmithKline Pharmaceuticals's ROC % is 74.77% (calculated using TTM income statement data). GlaxoSmithKline Pharmaceuticals generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


GlaxoSmithKline Pharmaceuticals ROC % Related Terms


GlaxoSmithKline Pharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals ROC % Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.62 42.93 49.57 71.20 78.52

GlaxoSmithKline Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.64 61.31 69.50 77.89 83.05
NSE:GLAXO
73GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pharmaceuticals ROC % Calculation

GlaxoSmithKline Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2026 is calculated as:

ROC % (A: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2025 ) + Invested Capital (A: Mar. 2026 ))/ count )
=12475.698 * ( 1 - 26.32% )/( (11300.35 + 12113.904)/ 2 )
=9192.0942864/11707.127
=78.52 %

where

Invested Capital(A: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=41080.655 - 14733.043 - ( 24981.036 - max(0, 19051.546 - 34098.808+24981.036))
=11300.35

Invested Capital(A: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=43238.664 - 12845.152 - ( 27563.422 - max(0, 17791.033 - 36070.641+27563.422))
=12113.904

GlaxoSmithKline Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=13510.4 * ( 1 - 25.53% )/( (0 + 12113.904)/ 1 )
=10061.19488/12113.904
=83.05 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=43238.664 - 12845.152 - ( 27563.422 - max(0, 17791.033 - 36070.641+27563.422))
=12113.904

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 83.05% mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a ROC % of 83.05% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors.
Is GlaxoSmithKline Pharmaceuticals' ROC % too high?
GlaxoSmithKline Pharmaceuticals' current ROC % is 83.05%. The Drug Manufacturers industry median ROC % is 4.44. GlaxoSmithKline Pharmaceuticals' value of 83.05% is 1770.5% above this industry median. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' ROC % compare to LLY and JNJ?
GlaxoSmithKline Pharmaceuticals' ROC % of 83.05% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.44. GlaxoSmithKline Pharmaceuticals' value of 83.05% is 1770.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pharmaceuticals's current ROC % of 83.05% is 1770.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current ROC % is 83.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,614.23, compared to a current price of ₹2,354.80 — trading 9.9% below its estimated fair value. The current ROC % is 83.05% and 1770.5% above the Drug Manufacturers industry median of 4.44. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current ROC % is 83.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued. The current stock price of ₹2,354.80 is trading 9.9% below its estimated GF Value™ of ₹2,614.23. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NSE:GLAXO:

  • ROC %: 83.05%
  • GF Value™: ₹2,614.23 vs. price of ₹2,354.80 (9.9% below fair value)
  • GF Score™: 73/100 with 1 warning sign
  • Industry Position: 1770.5% above the Drug Manufacturers median

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score

Get the complete analysis for NSE:GLAXO

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,354.80
Price
₹2,614.23
GF Value